Patents
Literature
53837 results about "Pharmacology" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Pharmacology is the branch of pharmaceutical sciences which is concerned with the study of drug or medication action, where a drug can be broadly defined as any man-made, natural, or endogenous (from within the body) molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism (sometimes the word pharmacon is used as a term to encompass these endogenous and exogenous bioactive species). More specifically, it is the study of the interactions that occur between a living organism and chemicals that affect normal or abnormal biochemical function. If substances have medicinal properties, they are considered pharmaceuticals.
Degraders and uses thereof
PCT designated stage expiredWO2025096855A1Organic active ingredientsOrganic chemistryBiochemistryPharmacology
The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic protein.
Owner:KUMQUAT BIOSCIENCES INC
Benzopyridinones and benzopyrimidinones as PI3k inhibitors
PCT designated stage expiredWO2025038395A1Group 4/14 element organic compoundsOrganic active ingredientsDiseasePharmacology
Owner:ONKURE INC
Polycyclic compound, preparation methods and medicinal uses thereof
PCT designated stage expiredWO2025092986A1Organic active ingredientsOrganic chemistryPolycyclic compoundDisease
Compounds of formula (I) useful as cancer treatment, the preparation method thereof, pharmaceutical compositions comprising the compounds, and the pharmaceutical uses for the treatment of certain diseases or disorders are disclosed.
Owner:JIANGSU HANSOH PHARMA CO LTD +2
Fused ring compound and use thereof in KRAS inhibitor
PCT designated stage expiredWO2025077770A1Organic active ingredientsOrganic chemistryMetaboliteKras mutation
A fused ring compound, a pharmaceutical composition comprising same, and the use thereof. The compound has a structure as represented by formula (I), or is a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture form thereof, a metabolite, a metabolic precursor, an isotope-substituted form, a pharmaceutically acceptable salt, a hydrate, a solvate, a polymorph or a co-crystal thereof. The compound can be used for treating one or more cancers caused by KRAS mutation.
Owner:CHENGDU HYPERWAY PHARM CO LTD +1
KRAS inhibitors
PCT designated stage expiredWO2025096738A1Organic active ingredientsOrganic chemistryDiseaseOncology
Owner:INCYTE CORP
Spirocyclic dihydropyranopyrimidine KRAS inhibitors
PCT designated stage expiredWO2025038936A1Organic chemistryAntineoplastic agentsDihydropyridinePharmaceutical medicine
Provided herein are compounds of Formula (IV-b), or pharmaceutically acceptable salts thereof, that inhibit a KRas protein (e.g., a dysregulated KRas protein (e.g., a mutated or amplified KRas protein)). This disclosure also provides compositions containing the compounds as provided herein, or pharmaceutically acceptable salts thereof, as well as methods of using and making the same.
Owner:TREELINE BIOSCIENCES INC
Compositions of hydroxypropyl-β-cyclodextrin and methods of purifying the same
ActiveUS12215174B2Organic active ingredientsPharmaceutical delivery mechanismCyclodextrinMedicinal chemistry
The present disclosure relates to compositions comprising mixtures of hydroxypropyl-β-cyclodextrin, wherein the compositions may be isomerically purified. The disclosure also relates to methods of isomerically purifying a mixture of hydroxypropyl-β-cyclodextrins.
Owner:BEREN THERAPEUTICS PBC
PARP-inhibitor nanoparticles and methods thereof
PCT designated stage expiredWO2025024581A1Powder deliveryEnergy modified materialsPhotodynamic therapyNanoparticle
This present disclosure is directed to poly (ADP-ribose) polymerase (PARP) inhibitor nanoparticle composition and methods of use and preparation thereof. PARP inhibitor dose reduction through combination treatment may be achieved using photodynamic therapy or photoimmunotherapy.
Owner:UNIV OF MARYLAND
Ribonucleotide reductase (RNR) compositions and methods of use
PCT designated stage expiredWO2025049814A2Antibody ingredientsAntineoplastic agentsNucleotideOncology
Provided herein are methods of treatment comprising administering a selective ribonucleotide reductase (RNR) inhibitor in combination with other therapeutic agents, thereby treating cancer and preventing or reversing resistance to the therapeutic agents.
Owner:BOUNDLESS BIO INC
KRAS(G12D) inhibitors
The present invention is directed to the compounds of Formula (A) inhibitors of KRAS(G12D). The inhibitors described herein can be useful in the treatment of diseases or disorders associated with KRAS(G12D), such as Lung cancer, Pancreatic cancer, Colorectal cancer et al. In particular, the invention is concerned with compounds and pharmaceutical compositions inhibiting KRAS(G12D), methods of treating diseases or disorders associated with KRAS(G12D), and methods of synthesizing these compounds.
Owner:WINDERMERE THERAPEUTICS INC
Purple KRAS inhibitors and uses thereof
PendingCN119661539ASilicon organic compoundsSilicon compound active ingredientsBiochemistryDrug resistance
The invention discloses a general KRAS inhibitor, the structure of which is shown as a formula I. In the formula, the definition of each substituent group is shown in the description and claims. The general KRAS inhibitor has the advantages of easily available raw materials, simple synthesis, wide action range and strong effect, and can reduce or avoid the possibility of drug resistance generation. # imgabs0 #
Owner:SHANGHAI JIAOTONG UNIV
Ras-PI3k inhibitors and uses thereof
PCT designated stage expiredWO2025096957A1Organic active ingredientsOrganic chemistryBiochemistryPharmacology
Owner:VIVIDION THERAPEUTICS INC
Combination cancer therapies with a KRAS modulator and an RTK-MAPK pathway inhibitor
PCT designated stage expiredWO2025106901A1Organic active ingredientsAntibody ingredientsKRASOncology
Provided herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a RTK-MAPK pathway inhibitor and a compound of Formula (I).
Owner:QUANTA THERAPEUTICS INC
Crystalline forms of a KRAS inhibitor
This disclosure provides salts, crystalline forms, and formulations of a KRAS inhibitor, and methods of making and using thereof.
Owner:INCYTE CORP
Phosphoinositide 3-kinase allosteric inhibitor for treating disease related to PI3k regulation
PCT designated stage expiredWO2025040167A1Organic active ingredientsOrganic chemistryDiseasePharmaceutical medicine
Disclosed in the present invention is a phosphoinositide 3-kinase allosteric inhibitor for treating a disease related to PI3K regulation. Specifically, provided is a compound as represented by formula I or a pharmaceutically acceptable salt thereof. The phosphoinositide 3-kinase allosteric inhibitor of the present invention can effectively conduct allosteric targeted inhibition on a PI3Kα mutation, in particular, a PI3KαH1047R mutation, has relatively good selectivity, and is expected to treat and / or prevent related diseases or disorders.
Owner:SHANGHAI ALLIST PHARM CO LTD
Heterocyclic compounds, compositions thereof, and methods of treatment therewith
PCT designated stage expiredWO2025108443A2Organic active ingredientsOrganic chemistryMedicinal chemistryPharmacology
Provided herein are compounds having the following structure (I), wherein the substituents are as defined herein, compositions comprising a compound, and methods for modulating the activity of KRAS G12D.
Owner:BEIGENE SWITZERLAND GMBH +1
Chemical compounds
PCT designated stage expiredWO2025007074A1Boron compound active ingredientsGroup 3/13 element organic compoundsDiseaseChemical compound
Owner:AN2 THERAPEUTICS INC
Combination therapies with a KRAS modulator and an immunomodulator inhibitor
PCT designated stage expiredWO2025106905A1Organic active ingredientsImmunoglobulinsOncologyPharmacology
Provided herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of an immunomodulator inhibitor and a compound of Formula (I).
Owner:QUANTA THERAPEUTICS INC
Compound targeting protein modulator and use thereof
PCT designated stage expiredWO2025103476A1Organic active ingredientsOrganic chemistryProtein targetPharmacology
Owner:SHANGHAI PHARMACEUTICALS HOLDING CO LTD
Pulmonary therapy for sleep disordered breathing care
PCT designated stage expiredWO2025076527A1ElectrotherapyArtificial respirationTreatment sleepSleep disordered breathing
Methods and / or devices to deliver pulmonary therapy to treat sleep disordered breathing are disclosed.
Owner:INSPIRE MEDICAL SYSTEMS INC
Ras inhibitors and methods of use thereof
The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as cancer. The compounds are contemplated to be modulators of Ras (e.g., K-Ras).
Owner:KESTREL THERAPEUTICS INC
Heterocyclic compounds, compositions thereof, and methods of treatment therewith
PCT designated stageWO2025168072A1Organic active ingredientsOrganic chemistryMedicinal chemistryPharmacology
Provided herein are compounds having the following structure (I), wherein the substituents are as defined herein, compositions comprising a compound, and methods for modulating the activity of KRAS G12D and / or G12V.
Owner:BEIGENE (SUZHOU) CO., LTD. +1
Short-pulse sonodynamic treatment apparatus
Sonodynamic therapy systems and methods use short, high-pressure ultrasound pulses that produce small (and therefore clinically safe) increases (up to 1-2° C.) in tissue temperature but nonetheless activate sonodynamic agents, allowing isolated single-cav-itation events to produce therapeutically beneficial effects (e.g., cytotoxicity) on diseased tissue. An escalating sonication strategy may be employed whereby the focal pressure is gradually increased until maximum clinically tolerable parameters such as the degree of heating of intervening tissue (e.g., the skull when treating brain cancer) or undesired induced cavitation effects are reached.
Owner:INSIGHTEC
Compositions and methods for treating neurocognitive disorders
To provide methods for treating a subject having or at risk of developing a neurocognitive disorder, such as frontotemporal lobar degeneration or neuronal ceroid lipofuscinosis.SOLUTION: Provided is a method comprising administering, to a subject diagnosed as having a neurocognitive disorder (NCD), a composition comprising a population of cells comprising a transgene encoding a progranulin (PGRN) or a granulin (GRN).SELECTED DRAWING: Figure 1A
Owner:AVROBIO INC
Epinephrine compositions and containers
ActiveUS20250120923A1Organic active ingredientsPharmaceutical delivery mechanismOrganic chemistryMedicinal chemistry
A sterile storage stable ready-to-inject epinephrine composition contained within a flexible container and packaged within a secondary container, the composition including an aqueous pharmaceutically acceptable carrier containing epinephrine and a metal ion chelator, the epinephrine being present in a concentration of equal to or less than 0.07 mg / mL, substantially all of the epinephrine being an R-isomer, the composition having a pH of between 3.5-4.7, and the composition having, after storage of at least one month at 25° C., total impurities of equal or less than 0.7% and equal or less than 4% S-isomer content.
Owner:NEVAKAR INJECTABLES INC
Epinephrine spray formulations
ActiveUS12295921B2Organic active ingredientsDispersion deliveryAnaphylactic reactionsBiomedical engineering
Provided herein are epinephrine spray formulations. Also provided herein are methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatment.
Owner:BRYN PHARMA LLC
Treatment with anti-α4β7 antibody
Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
Owner:TAKEDA PHARMA CO LTD
Cyclic peptide compounds and compositions as ras inhibitors
This disclosure provides cyclic peptide compounds of formula (A) or formula (II) as inhibitors of Ras kinase, and compositions and use of the same in treating diseases associated with Ras kinase.
Owner:SYNERON TECHNOLOGY CO LTD +1
Pharmaceutically acceptable salt of g12d inhibitor compound and crystal form thereof
PCT designated stageWO2025157260A1Organic active ingredientsOrganic chemistryMethyl palmoxiratePharmacology
The present disclosure relates to a pharmaceutically acceptable salt of a G12D inhibitor compound and a crystal form thereof. Specifically, provided in the present disclosure are a salt of 2-amino-4-((5S,5aS,6S,9R)-12-((1-((4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-1-fluoro-5-methyl-5a,6,7,8,9,10-hexahydro-5H-4-oxa-3,10a,11,13,14-pentaaza-6,9-methanonaphtho[1,8-ab]cyclohepten-2-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and a crystal form thereof.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1
Treatment of treatment resistant depression with psilocybin
The disclosure provides methods for treating treatment-resistant depression a subject in need thereof comprising administering to the subject two or more doses of psilocybin. The methods described herein may be used to treat subjects both responsive and unresponsive to a first dose of psilocybin
Owner:COMPASS PATHFINDER LTD